SABCS 2025 Explores GLP-1 Drug Impact
The Society of Breast Cancer Surgical Oncology (SABCS) 2025 conference has spotlighted emerging research into the use of GLP-1 receptor agonists—which originally gained fame for treating diabetes and obesity—in breast cancer management. These medications, including semaglutide and liraglutide, are now being studied for their potential to improve treatment outcomes and patient quality of life.
GLP-1 drugs work by stimulating insulin secretion and promoting satiety. Early-phase trials presented at SABCS suggest they may also reduce tumor growth, enhance the effects of established therapies, and mitigate treatment-related side effects such as fatigue and cachexia. Dr. Emily Carter, a leading oncology researcher, noted that “the anti-inflammatory and metabolic benefits of GLP-1 agonists could revolutionize how we support patients undergoing chemotherapy or radiation.”
A key study involved women with early-stage breast cancer receiving standard neoadjuvant therapy combined with semaglutide. Results indicated a 15% greater reduction in tumor size compared to the control group, alongside improved glucose control and body composition. Researchers hypothesize that the drugs may create a less hospitable microenvironment for cancer cells by reducing insulin-like growth factor signaling.
Another presentation focused on palliative care, where GLP-1 therapy helped manage cachexia and weight loss in advanced breast cancer patients. Over six months, participants experienced stabilized body mass indices and reported better appetite and mood. These findings align with broader trends in oncology, where metabolic health is increasingly recognized as a critical component of comprehensive care.
Challenges remain, including drug accessibility, cost, and the need for large-scale randomized trials to confirm long-term benefits. Regulatory agencies have not yet approved GLP-1 drugs specifically for oncology use, though advocacy groups are pushing for expedited reviews. If validated, these therapies could become standard adjuncts to surgery, chemotherapy, and hormonal therapy, offering patients a new tool in their fight against breast cancer.
Image Source: Google | Image Credit: Respective Owner
